ValiRx (LSE:VAL) Additional Paid-In Capital : £27.87 Mil(As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Additional Paid-In Capital?

ValiRx's quarterly additional paid-in capital increased from Jun. 2022 (£24.52 Mil) to Dec. 2022 (£26.77 Mil) and increased from Dec. 2022 (£26.77 Mil) to Jun. 2023 (£27.87 Mil).

ValiRx's annual additional paid-in capital increased from Dec. 2020 (£24.38 Mil) to Dec. 2021 (£24.49 Mil) and increased from Dec. 2021 (£24.49 Mil) to Dec. 2022 (£26.77 Mil).

ValiRx Additional Paid-In Capital Historical Data

The historical data trend for ValiRx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Additional Paid-In Capital Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

19.78

20.60

24.38

24.49

26.77

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															24.40	24.49	24.52	26.77	27.87

ValiRx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

ValiRx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ValiRx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.